Literature DB >> 31093881

Specific and Selective Bacteriophages in the Fight against Multidrug-resistant Acinetobacter baumannii.

Natalia Bagińska1, Anna Pichlak1, Andrzej Górski1,2,3, Ewa Jończyk-Matysiak4.   

Abstract

Acinetobacter baumannii causes serious infections especially in immunocompromised and/or hospitalized patients. Several A. baumannii strains are multidrug resistant and infect wounds, bones, and the respiratory tract. Current studies are focused on finding new effective agents against A. baumannii. Phage therapy is a promising means to fight this bacterium and many studies on procuring and applying new phages against A. baumannii are currently being conducted. As shown in animal models, phages against multidrug-resistant A. baumannii may control bacterial infections caused by this pathogen and may be a real hope to solve this dangerous health problem.

Entities:  

Keywords:  Acinetobacter baumannii; Bacteriophages; Multidrug resistance (MDR); Phage therapy

Mesh：

Substances：

Year:  2019        PMID： 31093881      PMCID： PMC6687786          DOI： 10.1007/s12250-019-00125-0

Source DB:  PubMed          Journal:  Virol Sin        ISSN： 1995-820X            Impact factor:   4.327


  57 in total

Review 1.  Bacteriophage therapy.

Authors:  A Sulakvelidze; Z Alavidze; J G Morris
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Back to basics--optimizing the use of available resources during an outbreak of multi-drug resistant Acinetobacter spp.

Authors:  G De Jong; A Duse; G Richards; E Marais
Journal:  J Hosp Infect       Date:  2004-06       Impact factor: 3.926

3.  Carbapenem-resistant Acinetobacter and role of curtains in an outbreak in intensive care units.

Authors:  I Das; P Lambert; D Hill; M Noy; J Bion; T Elliott
Journal:  J Hosp Infect       Date:  2002-02       Impact factor: 3.926

4.  Environmental contamination during a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit.

Authors:  G Aygün; O Demirkiran; T Utku; B Mete; S Urkmez; M Yilmaz; H Yaşar; Y Dikmen; R Oztürk
Journal:  J Hosp Infect       Date:  2002-12       Impact factor: 3.926

5.  OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain.

Authors:  G Bou; A Oliver; J Martínez-Beltrán
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

6.  Eradication of multi-drug resistant Acinetobacter from an intensive care unit.

Authors:  Y D Podnos; M E Cinat; S E Wilson; J Cooke; W Gornick; L D Thrupp
Journal:  Surg Infect (Larchmt)       Date:  2001       Impact factor: 2.150

7.  Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system.

Authors:  Andrew P Tomaras; Caleb W Dorsey; Richard E Edelmann; Luis A Actis
Journal:  Microbiology       Date:  2003-12       Impact factor: 2.777

Review 8.  Acinetobacter outbreaks, 1977-2000.

Authors:  Maria Virginia Villegas; Alan I Hartstein
Journal:  Infect Control Hosp Epidemiol       Date:  2003-04       Impact factor: 3.254

9.  Treatment of experimental infections of mice with bacteriophages.

Authors:  J S Soothill
Journal:  J Med Microbiol       Date:  1992-10       Impact factor: 2.472

10.  Bacteriological and physiological research styles in the early controversy on the nature of the bacteriophage phenomenon.

Authors:  T van Helvoort
Journal:  Med Hist       Date:  1992-07       Impact factor: 1.419
View more
  9 in total

Review 1.  Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat.

Authors:  David A Butler; Mark Biagi; Xing Tan; Samah Qasmieh; Zackery P Bulman; Eric Wenzler
Journal:  Curr Infect Dis Rep       Date:  2019-11-16       Impact factor: 3.725

2.  Isolation and genomic analysis of temperate phage 5W targeting multidrug-resistant Acinetobacter baumannii.

Authors:  Wenyi Peng; Fei Zeng; Zhiying Wu; Zeyuan Jin; Wanxia Li; Mingzhuo Zhu; Qiuping Wang; Yigang Tong; Lili Chen; Qinqin Bai
Journal:  Arch Microbiol       Date:  2021-12-23       Impact factor: 2.552

Review 3.  Antimicrobial Peptides and Cationic Nanoparticles: A Broad-Spectrum Weapon to Fight Multi-Drug Resistance Not Only in Bacteria.

Authors:  Giulia E Valenti; Silvana Alfei; Debora Caviglia; Cinzia Domenicotti; Barbara Marengo
Journal:  Int J Mol Sci       Date:  2022-05-29       Impact factor: 6.208

Review 4.  Evasion of Antimicrobial Activity in Acinetobacter baumannii by Target Site Modifications: An Effective Resistance Mechanism.

Authors:  Arturo Martínez-Trejo; Juan Manuel Ruiz-Ruiz; Luis Uriel Gonzalez-Avila; Andrés Saldaña-Padilla; Cecilia Hernández-Cortez; Miguel Angel Loyola-Cruz; Juan Manuel Bello-López; Graciela Castro-Escarpulli
Journal:  Int J Mol Sci       Date:  2022-06-13       Impact factor: 6.208

5.  Critically Ill Patient with Multidrug-Resistant Acinetobacter baumannii Respiratory Infection Successfully Treated with Intravenous and Nebulized Bacteriophage Therapy.

Authors:  Sohail Rao; Monica Betancourt-Garcia; Yetunde O Kare-Opaneye; Brett E Swierczewski; Jason W Bennett; Bri'Anna Horne; Joseph Fackler; Lia Patricia Suazo Hernandez; Michael J Brownstein
Journal:  Antimicrob Agents Chemother       Date:  2021-10-18       Impact factor: 5.938

6.  Death from pan-resistant superbug.

Authors:  Larry Nichols
Journal:  Autops Case Rep       Date:  2019-07-19

Review 7.  Interplay between ESKAPE Pathogens and Immunity in Skin Infections: An Overview of the Major Determinants of Virulence and Antibiotic Resistance.

Authors:  Gustavo Henrique Rodrigues Vale de Macedo; Gabrielle Damasceno Evangelista Costa; Elane Rodrigues Oliveira; Glauciane Viera Damasceno; Juliana Silva Pereira Mendonça; Lucas Dos Santos Silva; Vitor Lopes Chagas; José Manuel Noguera Bazán; Amanda Silva Dos Santos Aliança; Rita de Cássia Mendonça de Miranda; Adrielle Zagmignan; Andrea de Souza Monteiro; Luís Cláudio Nascimento da Silva
Journal:  Pathogens       Date:  2021-02-02

Review 8.  Development and Research Progress of Anti-Drug Resistant Bacteria Drugs.

Authors:  Xiangyi Cui; Yuhong Lü; Changwu Yue
Journal:  Infect Drug Resist       Date:  2021-12-21       Impact factor: 4.003

9.  The endolysin of the Acinetobacter baumannii phage vB_AbaP_D2 shows broad antibacterial activity.

Authors:  Yuyu Yuan; Xiaoyu Li; Lili Wang; Gen Li; Cong Cong; Ruihua Li; Huijing Cui; Bilal Murtaza; Yongping Xu
Journal:  Microb Biotechnol       Date:  2020-06-10       Impact factor: 5.813
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.